Suppr超能文献

混合嵌合体诱导的移植耐受

Transplantation tolerance induced by mixed chimerism.

作者信息

Wekerle T

机构信息

Division of Transplantation, Department of Surgery, Vienna General Hospital, University of Vienna, Vienna, Austria.

出版信息

J Heart Lung Transplant. 2001 Aug;20(8):816-23. doi: 10.1016/s1053-2498(01)00265-0.

Abstract

Although short- and long-term results after organ transplantation have improved considerably in recent years, morbidity and mortality rates in graft recipients remain high. The induction of lifelong donor-specific tolerance would dramatically improve outcome after organ transplantation. Although many tolerance protocols have been successful in rodent studies, most of these approaches have failed when attempted in large animals or humans. Robust tolerance, in contrast, has been demonstrated with mixed chimerism regimens not only in rodents but also in large animal models, including non-human primates. Furthermore, mixed chimerism protocols have been developed that would be feasible in cadaveric, and thus in thoracic, transplantation. The induction of mixed hematopoietic chimerism is therefore an attractive experimental approach for development of clinical tolerance protocols. One of the obstacles to widespread clinical application of this concept is the remaining toxicity of the host conditioning. Recent advances, however, have led to substantially milder protocols that could become clinically acceptable in the foreseeable future. This article provides a short overview of the basic mechanisms by which immunologic tolerance may be induced, describes the concept of mixed chimerism as a promising approach for clinical tolerance induction, and reviews recent progress in developing clinically feasible mixed chimerism protocols.

摘要

尽管近年来器官移植后的短期和长期效果有了显著改善,但移植受者的发病率和死亡率仍然很高。诱导终身供体特异性耐受将极大地改善器官移植后的结果。虽然许多耐受方案在啮齿动物研究中取得了成功,但这些方法大多在大型动物或人类试验时失败了。相比之下,不仅在啮齿动物中,而且在包括非人灵长类动物在内的大型动物模型中,混合嵌合体方案都已证明能产生强大的耐受性。此外,已经开发出在尸体移植(包括胸科移植)中可行的混合嵌合体方案。因此,诱导混合造血嵌合体是开发临床耐受方案的一种有吸引力的实验方法。这一概念广泛临床应用的障碍之一是宿主预处理仍存在毒性。然而,最近的进展已产生了实质上更温和的方案,在可预见的未来可能会被临床接受。本文简要概述了诱导免疫耐受的基本机制,描述了混合嵌合体作为临床耐受诱导的一种有前景方法的概念,并综述了开发临床可行的混合嵌合体方案的最新进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验